These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 26519290)
1. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model. Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725 [TBL] [Abstract][Full Text] [Related]
3. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus. Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391 [TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model. Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969 [TBL] [Abstract][Full Text] [Related]
6. Isolate-dependent use of claudins for cell entry by hepatitis C virus. Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920 [TBL] [Abstract][Full Text] [Related]
7. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173 [TBL] [Abstract][Full Text] [Related]
8. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape. Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099 [TBL] [Abstract][Full Text] [Related]
9. [Claudin 1 as a target for anti-hepatitis C virus strategy]. Fukasawa M Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046 [TBL] [Abstract][Full Text] [Related]
10. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. Lacek K; Vercauteren K; Grzyb K; Naddeo M; Verhoye L; Słowikowski MP; Fafi-Kremer S; Patel AH; Baumert TF; Folgori A; Leroux-Roels G; Cortese R; Meuleman P; Nicosia A J Hepatol; 2012 Jul; 57(1):17-23. PubMed ID: 22414763 [TBL] [Abstract][Full Text] [Related]
11. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer. Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141 [TBL] [Abstract][Full Text] [Related]
12. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection. Bose M; Mullick R; Das S; Das S; Karande AA Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733 [TBL] [Abstract][Full Text] [Related]
13. Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. Sarhan MA; Chen AY; Michalak TI PLoS One; 2013; 8(4):e62159. PubMed ID: 23626783 [TBL] [Abstract][Full Text] [Related]
14. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J J Virol; 2018 May; 92(10):. PubMed ID: 29491159 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244 [TBL] [Abstract][Full Text] [Related]
16. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204 [TBL] [Abstract][Full Text] [Related]
17. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483 [TBL] [Abstract][Full Text] [Related]
19. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. Meertens L; Bertaux C; Cukierman L; Cormier E; Lavillette D; Cosset FL; Dragic T J Virol; 2008 Apr; 82(7):3555-60. PubMed ID: 18234789 [TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model. Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]